AbbVie, Alphabet’s Calico end 11-year partnership in aging researchnews2025-11-13T16:09:58+00:00November 13th, 2025|Endpoints News|
MacroGenics stops work on a bispecific; Third Arc Bio makes a deal with Adagenenews2025-11-13T15:56:22+00:00November 13th, 2025|Endpoints News|
Day One to buy struggling ADC maker Mersana for $129Mnews2025-11-13T15:54:28+00:00November 13th, 2025|Endpoints News|
Abeona’s skin disease cell therapy launch stymied by false-positive sterility testnews2025-11-13T15:43:19+00:00November 13th, 2025|Endpoints News|
Q&A: BioNTech co-founders discuss immuno-oncology efforts, Bristol Myers dealnews2025-11-13T15:00:44+00:00November 13th, 2025|Endpoints News|
Merck KGaA still in tariff talks with the White House, weeks after deal was announced news2025-11-13T14:29:36+00:00November 13th, 2025|Endpoints News|
Mental health companies, once wary of AI, are building chatbotsnews2025-11-13T14:00:56+00:00November 13th, 2025|Endpoints News|
Gate Bioscience captures another $65M with new take on protein degradationnews2025-11-13T13:00:51+00:00November 13th, 2025|Endpoints News|
Q&A: Bausch + Lomb CEO Brent Saunders on turnaround, AI, TrumpRxnews2025-11-13T12:00:49+00:00November 13th, 2025|Endpoints News|
Korro Bio abandons lead genetic disease drug candidate after disappointing datanews2025-11-13T11:56:02+00:00November 13th, 2025|Endpoints News|
